Wu, Y. et al.. A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nature Communications
Effective annual influenza vaccination requires frequent changes in vaccine composition due to both antigenic shift for different subtype hemagglutinins (HAs) and antigenic drift in a particular HA. Here we present a broadly neutralizing human monoclonal antibody with an unusual binding modality. The antibody, designated CT149, was isolated from convalescent patients infected with pandemic H1N1 in 2009. CT149 is found to neutralize all tested group 2 and some group 1 influenza A viruses by inhibiting low pH-induced, HA-mediated membrane fusion. It promotes killing of infected cells by Fc-mediated antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. X-ray crystallographic data reveal that CT149 binds primarily to the fusion domain in HA2, and the light chain is also largely involved in binding. The epitope recognized by this antibody comprises amino-acid residues from two adjacent protomers of HA. This binding characteristic of CT149 will provide more information to support the design of more potent influenza vaccines.
See Also:
Latest articles in those days:
- The evolution and transmission dynamics of H3N2 influenza virus identified in a respiratory disease outbreak in companion dogs in Alabama, USA 11 hours ago
- Structural and functional characterization of hemagglutinin E190D and Q226H minor variants in human H5N1 A/British Columbia/PHL-2032/2024 11 hours ago
- Spatial risk factors associated with outbreaks of highly pathogenic avian influenza in Pennsylvania’s commercial poultry farms 11 hours ago
- [preprint]H9N2 avian influenza virus in Bangladesh: three genetically distinct co-circulating subgroups retain a largely conserved antigenic phenotype 12 hours ago
- [preprint]Endogenous serine proteases in MDCK sublines support trypsin-independent influenza A virus replication 12 hours ago
[Go Top] [Close Window]


